Chukwuemeka Ihemelandu, MD, explains the role of surgery in prolonging life and disease progression in patients with upper gastrointestinal cancers.
Chukwuemeka Ihemelandu, MD, an associate professor of Surgical Oncology at Georgetown University Medical School, explain the role of surgery in prolonging life and disease progression in patients with upper gastrointestinal cancers.
According to Ihemelandu, surgery it the best option for patients with metastatic disease. He stresses, however, that the benefit of surgery depends on how soon after diagnosis the surgery occurs. In cases where surgical interventional occurs early on, patients are more likely to move on to systemic therapy and have better survival outcomes.
0:07| So, for patients who present with metastatic disease, what's going to offer them the best survival benefit is the surgery itself. And what do I mean by that? It's being able to remove as much of the disease as possible. Now, the earlier the patients get to us the better for the patients because we're able to clear them up all their disease.
0:26| You know, we've published data and most other centers that do what we do have published data that shows that if you're able to clear the patients of all their disease, or at least a great majority of the disease, those are the patients that do well. And so, from a surgical standpoint, we're pushing for those patients who we can actually take to the apparent room and get rid of the majority of the disease. And after we've done that, we then treat them with what we call the heated intraperitoneal chemotherapy to address the microscopic disease or residual disease will leave him behind.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More